The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
The US Food and Drug Administration has approved a combination intravenous treatment for follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
The FDA has posted a correction for this press release: "The notice posted to the Hematology/Oncology Approvals web page yesterday afternoon regarding an approval for the treatment of Hodgkin lymphoma...
